| 摘要 |
The invention provides new methods of treatment using TGF-&bgr;3 to inhibit scarring in humans, and TGF-&bgr;3 for new uses in the inhibition of scarring in humans. In a first incidence of treatment each centimetre of wound margin, or each centimetre of a site at which a wound is to be formed, is provided with between approximately 350 ng and 1000 ng of TGF-&bgr;3; and in a second incidence of treatment, occurring after a wound is formed, and between 8 and 48 hours after the first incidence of treatment, the wound is provided with an amount of between approximately 350 ng and 1000 ng of TGF-&bgr;3 per centimetre of wound margin in which scarring is to be inhibited. The amount of TGF-&bgr;3 provided may be the same in each incidence of treatment. The amount of TGF-&bgr;3 provided per centimetre in each incidence of treatment may preferably be approximately 500 ng. The TGF-&bgr;3 may be provided by intradermal injection. Also provided are kits and methods of selecting an appropriate treatment regime for inhibiting scarring associated with the healing of a human wound. |
